Study population | Favourable outcome | Poor outcome | |||||
---|---|---|---|---|---|---|---|
N | N | N | p value | ||||
ICU stay duration, days | 80 | 29.5 [20–44] | 50 | 28.5 [21–45] | 30 | 29.5 [20–43] | 0.82 |
Tertiary hospital stay duration, days | 80 | 55 [43–78] | 50 | 57 [46–90] | 30 | 49 [37–64] | 0.02 |
Days free of MV at day 30, days | 72 | 3.7 [0–12] | 47 | 5 [0–12] | 25 | 0.8 [0–12] | 0.71 |
Days free of MV at day 60, days | 72 | 32.9 [20–41] | 47 | 35 [23–42] | 25 | 29.9 [1–37] | 0.11 |
Intubation to cannula ablation during or after acute care hospital stay, days | 54 | 42 [35–58] | 49 | 40 [34–48] | 5 | 76 [61–144] | < 0.01 |
ICU-acquired weakness diagnosis, n. (%) | 80 | 20 (25%) | 50 | 13 (26%) | 30 | 7 (23. 3%) | 0.79 |
With MRC score < 48/60, n. (%) | 80 | 17 (21.3%) | 50 | 11 (22%) | 30 | 6 (20%) | 1 |
With EMNG/high clinical suspicion, n. (%) | 80 | 3 (3.8%) | 50 | 2 (4%) | 30 | 1 (3.3%) | 1 |
MRC score value | 17 | 20 [0.5–32.5] | 11 | 20 [0–33] | 6 | 17.5 [5.3–35.5] | 0.9 |